References
- 1..Zhu C, Wu Q, Sheng T, Shi J, Shen X, Yu J, et al. Rationally designed approaches to augment CAR-T therapy for solid tumor treatment. Bioact Mater. 2024;33:377–95.
- 2..Liu H, Shen W, Liu W, Yang Z, Yin D, Xiao C. From oncolytic peptides to oncolytic polymers: a new paradigm for oncotherapy. Bioact Mater. 2024;31:206–30.
- 3..Dandia HY, Pillai MM, Sharma D, Suvarna M, Dalal N, Madhok A, et al. A cellular scaffold-based approach for in situ genetic engineering of host T-cells in solid tumor immunotherapy. Mil Med Res. 2024;11(1):3.
- 4..Dagher OK, JrPosey AD. Forks in the road for CAR T and CAR NK cell cancer therapies. Nat Immunol. 2023;24(12):1994–2007.
- 5..Walsh LA, Quail DF. Decoding the tumor microenvironment with spatial technologies. Nat Immunol. 2023;24(12):1982–93.
- 6..Liu L, Yoon CW, Yuan Z, Guo T, Qu Y, He P, et al. Cellular and molecular imaging of CAR-T cell-based immunotherapy. Adv Drug Deliv Rev. 2023;203: 115135.

